Pfizer Inc. $PFE Shares Bought by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors increased its Pfizer position by 49.5% in the second quarter, adding 130,842 shares for a total holding of 395,297 shares valued at approximately $9.5 million. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly earnings of $0.77 per share and revenue of $15.03 billion, exceeding analyst estimates, while revenue grew 2.6% year over year. Shares recently opened at $26.77, within their 52-week range of $23.58 to $28.75.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to an annualized yield of about 6.4%. Analysts maintain a consensus “Hold” rating with an average price target of $28.28, as investors weigh its post-COVID revenue declines and pipeline risks.

Farther Finance Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 49.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 395,297 shares of the biopharmaceutical company's stock after acquiring an additional 130,842 shares during the period. Farther Finance Advisors LLC's holdings in Pfizer were worth $9,522,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. LifeSteps Financial Inc. acquired a new position in shares of Pfizer during the second quarter worth about $128,000. Burns Matteson Capital Management LLC purchased a new stake in Pfizer in the 2nd quarter valued at approximately $490,000. Amplius Wealth Advisors LLC increased its position in Pfizer by 38.6% during the 2nd quarter. Amplius Wealth Advisors LLC now owns 14,251 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 3,966 shares during the period. Winthrop Advisory Group LLC lifted its holdings in shares of Pfizer by 5.4% in the 2nd quarter. Winthrop Advisory Group LLC now owns 14,384 shares of the biopharmaceutical company's stock valued at $346,000 after buying an additional 743 shares during the period. Finally, OFI Invest Asset Management boosted its stake in shares of Pfizer by 6,349.3% in the second quarter. OFI Invest Asset Management now owns 751,408 shares of the biopharmaceutical company's stock valued at $18,094,000 after buying an additional 739,757 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock opened at $26.77 on Monday. The stock has a fifty day moving average price of $25.12 and a 200 day moving average price of $26.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a market cap of $152.60 billion, a PE ratio of 35.23 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio is presently 226.32%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PFE. HSBC cut Pfizer from a "buy" rating to a "hold" rating and cut their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Guggenheim cut their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Pfizer in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source